CLAIMS

1. Use of deutetrabenazine in the manufacture of a medicament for treating chorea associated with Huntington's disease in a human transitioning from an existing daily amount of tetrabenazine for treating chorea associated with Huntington's disease to deutetrabenazine, the use comprising:

   a. discontinuing the daily amount of tetrabenazine;

   b. the next day, an initial daily amount of deutetrabenazine is to be administered to the human;

   wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg; or

   wherein the daily amount of tetrabenazine is 25 mg and the initial total daily amount of deutetrabenazine is 12 mg; or

   wherein the daily amount of tetrabenazine is 37.5 mg and the initial total daily amount of deutetrabenazine is 18 mg; or

   wherein the daily amount of tetrabenazine is 50 mg and the initial total daily amount of deutetrabenazine is 24 mg; or

   wherein the daily amount of tetrabenazine is 62.5 mg and the initial total daily amount of deutetrabenazine is 30 mg; or

   wherein the daily amount of tetrabenazine is 75 mg and the initial total daily amount of deutetrabenazine is 36 mg; or

   wherein the daily amount of tetrabenazine is 87.5 mg and the initial total daily amount of deutetrabenazine is 42 mg; or

   wherein the daily amount of tetrabenazine is 100 mg and the initial total daily amount of deutetrabenazine is 48 mg.

2. The use of claim 1, wherein the transitioning results in the chorea control is improved by a reduction of at least 0.5 points on the Total Maximal Chorea (TMC) score.

3. The use of claim 2, wherein the improvement is measured from a pre-treatment, baseline to maintenance therapy.

4. The use of claim 1, wherein the transitioning results in a reduction of chorea by at least 15%.

5. The use of claim 1, wherein:

(i) the transitioning results in a reduction of chorea by at least 10% and said use also provides at least one of the following:

motor function is improved by at least 10%;

the human's physical functioning is improved;

swallowing is improved;

balance is not worsened;

treatment causes no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia;

the maximal increases in QTcF is less than 5 ms;

or combinations thereof; or

(ii) motor function is improved by at least 10%, and said use also provides at least one of the following:

chorea is reduced by at least 10% ;

the human's physical functioning is improved;

swallowing is improved;

balance is not worsened;

treatment causes no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia;

the maximal increases in QTcF is less than 5 ms;

or combinations thereof.

6. The use of claim 1, wherein the initial daily amount is 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, 42 mg, or 48 mg and the initial daily amount is to be administered in two doses.

7. The use of claim 6, wherein:

the first dose is 6 mg and the second dose is 6 mg;

the first dose is 9 mg and the second dose is 9 mg;
the first dose is 12 mg and the second dose is 12 mg;
the first dose is 15 mg and the second dose is 15 mg;
the first dose is 18 mg and the second dose is 18 mg;
the first dose is 21 mg and the second dose is 21 mg; or
the first dose is 24 mg and the second dose is 24 mg.

8. The use of claim 7, further comprising:
   c) after about one week, determining the degree of control of abnormal involuntary movement achieved with the initial daily amount of the deutetrabenazine and the tolerability of the initial daily amount of the deutetrabenazine; and
   d) increasing the daily amount of the deutetrabenazine upward by 6 mg/day to a subsequent daily amount of the deutetrabenazine if the transitioning does not result in at least a maintenance of chorea control and the initial daily amount is tolerable.

9. The use of claim 8, further comprising:
   e) after about one week, repeating steps c) and d) in those humans wherein abnormal involuntary movement is reduced and the daily amount of deutetrabenazine is tolerated.

10. The use of claim 9, further comprising:
    decreasing the amount of deutetrabenazine by 6 mg/day to a subsequent daily amount in those humans wherein any subsequent daily amount is not tolerated.

11. The use of claim 9, further comprising repeating step e) until the degree of control of abnormal involuntary movement is adequate and the daily amount of deutetrabenazine is tolerable.

12. The use of claim 1, wherein the initial daily amount is 6 mg and is to be administered in one dose.

13. The use of claim 1, wherein the initial daily amount of deutetrabenazine is 6 mg, 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 42 mg, further comprising:

c) after about one week, determining the degree of control of abnormal involuntary movement achieved with the initial daily amount of the deutetrabenazine and the tolerability of the initial daily amount of the deutetrabenazine; and

d) increasing the daily amount of the deutetrabenazine by 6 mg/day to a subsequent daily amount in those humans wherein the transitioning does not result in at least a maintenance of chorea control and the initial daily amount is tolerable.

14. The use of claim 13, wherein the subsequent daily amount is 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 42 mg, further comprising:

e) after about one week, repeating steps c) and d) in those humans wherein abnormal involuntary movement is reduced and the daily amount of deutetrabenazine is tolerated.

15. The use of claim 14, wherein the daily amount is 18 mg, 24 mg, 30 mg, 36 mg, or 42 mg, further comprising repeating step e) until the degree of control of abnormal involuntary movement is adequate and the daily amount of deutetrabenazine is tolerable.

16. The use of claim 15, wherein the total maximum daily dose is 48 mg.

17. The use of claim 15, where in the total maximum daily dose is 36 mg.

18. The use of claim 17, wherein the human is concurrently receiving a strong CYP2D6 inhibitor.

19. The use of claim 18, wherein the strong CYP2D6 inhibitor is fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, or ritonavir.

20. The use of claim 19, wherein the strong CYP2D6 inhibitor is paroxetine, fluoxetine, or bupropion.

21. The use of claim 1, wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg.

22. The use of claim 1, wherein the daily amount of tetrabenazine is 25 mg and the initial total daily amount of deutetrabenazine is 12 mg.

23. The use of claim 22, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 6 mg and the second dose is 6 mg.

24. The use of claim 1, wherein the daily amount of tetrabenazine is 37.5 mg and the initial total daily amount of deutetrabenazine is 18 mg.

25. The use of claim 24, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 9 mg and the second dose is 9 mg.

26. The use of claim 1, wherein the daily amount of tetrabenazine is 50 mg and the initial total daily amount of deutetrabenazine is 24 mg.

27. The use of claim 26, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 12 mg and the second dose is 12 mg.

28. The use of claim 1, wherein the daily amount of tetrabenazine is 62.5 mg and the initial total daily amount of deutetrabenazine is 30 mg.

29. The use of claim 28, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 15 mg and the second dose is 15 mg.

30. The use of claim 1, wherein the daily amount of tetrabenazine is 75 mg and the initial total daily amount of deutetrabenazine is 36 mg.

31. The use of claim 30, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 18 mg and the second dose is 18 mg.

32. The use of claim 1, wherein the daily amount of tetrabenazine is 87.5 mg and the initial total daily amount of deutetrabenazine is 42 mg.

33. The use of claim 32, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 21 mg and the second dose is 21 mg.

34. The use of claim 1, wherein the daily amount of tetrabenazine is 100 mg and the initial total daily amount of deutetrabenazine is 48 mg.

35. The use of claim 34, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 24 mg and the second dose is 24 mg.

36. The use of claim 1, wherein the transitioning results in at least a maintenance of chorea control in the human.

37. The use of claim 1, wherein the initial total daily amount of deutetrabenazine is 6 mg, 12 mg, 18 mg, 24 mg, 30 mg, or 36 mg.

38. The use of claim 37, wherein the human is concurrently receiving a strong CYP2D6 inhibitor.

39. The use of claim 38, wherein the strong CYP2D6 inhibitor is fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, or ritonavir.

40. The use of claim 38, wherein the strong CYP2D6 inhibitor is paroxetine, fluoxetine, or bupropion.